To include your compound in the COVID-19 Resource Center, submit it here.

GALNS: Preliminary Extension study data

Preliminary data from the ongoing MOR-100 extension of the open-label, dose-escalation Phase I/II MOR-002 trial in about 15 patients showed that weekly

Read the full 229 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE